Data as of Mar 11
| -0.37 / -0.98%|
The 12 analysts offering 12-month price forecasts for Acorda Therapeutics Inc have a median target of 39.50, with a high estimate of 52.00 and a low estimate of 30.00. The median estimate represents a +5.70% increase from the last price of 37.37.
The current consensus among 12 polled investment analysts is to Hold stock in Acorda Therapeutics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.